Selecting innovative drug targets to build a pipeline of development programs
Focusing on small molecule drug discovery, Proximagen selects innovative drug targets to build a pipeline of development programs, each with the potential to provide a significant advance in the treatment of CNS and related disorders.
To more quickly and efficiently optimize new potential candidate drugs (CDs), we have in-house teams for each of the key disciplines needed for small molecule drug discovery, enabling close interaction and rapid decision-making. These teams include:
- Medicinal chemistry
- Drug metabolism and pharmacokinetics (DMPK)
- Early Stage Development